- $766.88m
- $537.68m
- $0.58m
Press Digest: British Business - Dec. 13
Brief: Icosavax Required To Pay Astrazeneca Finance And Holdings Termination Fee Of $27.2 Mln
Deals of the day-Mergers and acquisitions
France, Germany shares hit record highs, but give up gains after U.S CPI (updated)
AstraZeneca rises on deal to buy US-based Icosavax
Ftse 100 Hits 8: week high on slowing wage growth, but construction sector drags (updated)
Live Markets: European shares seen steadying at 22-month highs
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln (updated)
Brief: AstraZeneca Says To Acquire Icosavax for $1.1 bln
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Brief: Icosavax Announces Agreement To Be Acquired By Astrazeneca
Brief: Icosavax Announces Positive Topline Interim Phase 2 Results For Combination VLP Vaccine Candidate IVX-A12 Against RSV And HMPV In Older Adults
Brief: Icosavax Q3 Net Income USD -22.041 Million
Brief: Icosavax Q2 Net Income USD -26.497 Million
Brief: Icosavax Initiates Phase 2 Trial Of IVX-A12 Against RSV And HMPV In Older Adults
Icosavax rises on positive results of respiratory diseases vaccine
Brief: Icosavax Announces $67.8 Mln Registered Direct Offering Of Common Stock
Brief: Icosavax Announces Positive Topline Interim Phase 1 Results For Bivalent VLP Vaccine Candidate IVX-A12
Brief: Icosavax Announces Positive Interim Results From Phase 1 Clinical Trial Of IVX-A12